IL257379A - Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex - Google Patents
Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complexInfo
- Publication number
- IL257379A IL257379A IL257379A IL25737918A IL257379A IL 257379 A IL257379 A IL 257379A IL 257379 A IL257379 A IL 257379A IL 25737918 A IL25737918 A IL 25737918A IL 257379 A IL257379 A IL 257379A
- Authority
- IL
- Israel
- Prior art keywords
- nlrp3
- diacerin
- inflammasome
- asc
- analogs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562206102P | 2015-08-17 | 2015-08-17 | |
| PCT/US2016/047272 WO2017031161A1 (en) | 2015-08-17 | 2016-08-17 | Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL257379A true IL257379A (en) | 2018-04-30 |
Family
ID=58051269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL257379A IL257379A (en) | 2015-08-17 | 2018-02-06 | Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10195170B2 (https=) |
| EP (2) | EP3337782A4 (https=) |
| JP (3) | JP6887987B2 (https=) |
| KR (1) | KR20180037261A (https=) |
| CN (1) | CN108349867B (https=) |
| AU (2) | AU2016308121A1 (https=) |
| BR (1) | BR112018003212A2 (https=) |
| CA (1) | CA2994987C (https=) |
| IL (1) | IL257379A (https=) |
| MX (1) | MX2018002049A (https=) |
| RU (1) | RU2729066C2 (https=) |
| TW (1) | TWI743047B (https=) |
| WO (1) | WO2017031161A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
| EP3562506A4 (en) | 2016-12-29 | 2021-01-06 | University of Miami | METHOD TO MODULATE INFLAMMASOME ACTIVITY AND INFLAMMATION IN THE LUNG |
| CN110177547B (zh) | 2017-01-18 | 2022-09-27 | 台睿生物科技股份有限公司 | 用于治疗炎症性肠病和肠结肠炎的组合物 |
| WO2018225018A1 (en) | 2017-06-09 | 2018-12-13 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
| JP2020530472A (ja) * | 2017-08-11 | 2020-10-22 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | シュニッツラー症候群の治療方法 |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| WO2020010273A1 (en) | 2018-07-03 | 2020-01-09 | University Of Miami | Compositions and methods for treating inflammasome related diseases or conditions |
| KR102075724B1 (ko) * | 2018-09-14 | 2020-02-10 | 한국원자력의학원 | 디아세레인을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도 |
| IL283127B1 (en) | 2018-11-14 | 2026-02-01 | Smilebiotek Zhuhai Ltd | Animal-based models, scanning methods, and methods of treating intraocular diseases or disorders |
| ES2975968T3 (es) * | 2018-12-03 | 2024-07-18 | Smilebiotek Zhuhai Ltd | Galato de octilo y ésteres del mismo para uso en el tratamiento y prevención de la degeneración macular asociada a la edad causada por Bacillus Megaterium |
| EA202191968A1 (ru) | 2019-01-14 | 2021-11-16 | Кадила Хелзкэр Лимитед | Новые замещенные производные сульфонилмочевины |
| CN109833292A (zh) * | 2019-02-23 | 2019-06-04 | 河南省人民医院 | 一种双醋瑞因滴眼液及其用途 |
| US20220220480A1 (en) | 2019-04-17 | 2022-07-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders |
| CN110179865A (zh) * | 2019-06-26 | 2019-08-30 | 广州中医药大学(广州中医药研究院) | 一种大黄蒽醌类成分的制备方法及其应用 |
| CN110787157A (zh) * | 2019-11-27 | 2020-02-14 | 中南民族大学 | 双醋瑞因在用于舒张预收缩的气管平滑肌及治疗哮喘中的应用 |
| JP7072260B2 (ja) * | 2019-12-27 | 2022-05-20 | 国立大学法人愛媛大学 | マックル・ウェルズ症候群の治療用医薬組成物 |
| JP7459298B2 (ja) * | 2020-01-06 | 2024-04-01 | シーサン・セラピューティクス | 細胞透過性核酸複合体を有効成分として含有する黄斑変性の予防又は治療用組成物 |
| CN111358950A (zh) * | 2020-03-20 | 2020-07-03 | 厦门大学 | Caspase-1及ASC/Caspase-8作为靶点的应用 |
| WO2021198511A1 (en) | 2020-04-03 | 2021-10-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of sars-cov-2 infection |
| WO2022008597A1 (en) | 2020-07-08 | 2022-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of infectious diseases |
| WO2022084300A1 (en) | 2020-10-20 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosis and monitoring form of coronavirus infection |
| CN115616216B (zh) * | 2021-07-15 | 2025-08-12 | 华南理工大学 | 抑制或阻断faah与nlrp3之间相互作用的制剂的用途 |
| WO2024261302A1 (en) | 2023-06-22 | 2024-12-26 | Institut National de la Santé et de la Recherche Médicale | Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020128317A1 (en) | 2001-01-23 | 2002-09-12 | Laboratories Negma | Treatment of pathological conditions characterized by an increased IL-1 level |
| FR2842738B1 (fr) * | 2002-07-23 | 2006-02-10 | Negma Lerads | Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus |
| GB0404953D0 (en) * | 2004-03-04 | 2004-04-07 | Arakis Ltd | Pro-drugs |
| EP2300000A1 (en) * | 2008-07-03 | 2011-03-30 | University of Massachusetts | Methods and compositions for reducing inflammation and treating inflammatory disorders |
| TWI473610B (zh) * | 2008-10-28 | 2015-02-21 | Twi Biotechnology Inc | 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物 |
| CN102060809B (zh) * | 2009-05-01 | 2015-05-20 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种大黄酸衍生物及其制备和用途 |
| NZ602583A (en) * | 2010-04-08 | 2014-10-31 | Twi Biotechnology Inc | Methods of using diacerein as an adjunctive therapy for diabetes |
| WO2012013670A1 (en) * | 2010-07-29 | 2012-02-02 | University Of Geneva | Process for the esterification of hyaluronic acid with hydrophobic organic compounds |
| WO2012125359A1 (en) * | 2011-03-11 | 2012-09-20 | Twi Biotechnology, Inc. | Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia |
| WO2013007763A1 (en) * | 2011-07-12 | 2013-01-17 | Universität Zürich | MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE |
| US8652540B2 (en) * | 2012-06-04 | 2014-02-18 | Hong Kong Baptist University | Method of using rhein for treating fibrotic conditions and tumors |
| CN103110617A (zh) * | 2013-03-22 | 2013-05-22 | 中国人民解放军肾脏病研究所 | 一种双醋瑞因在制备治疗糖尿病肾病药物中的用途 |
| KR101486147B1 (ko) * | 2013-07-09 | 2015-01-23 | 주식회사 엘지생활건강 | Tslp 분비 저해능 및 이에 의한 알러지성 질환의 개선능을 가지는 조성물 |
| HK1249057A1 (zh) * | 2015-07-01 | 2018-10-26 | 安成生物科技股份有限公司 | 双醋瑞因或大黄酸局部用制剂及其用途 |
-
2016
- 2016-08-17 BR BR112018003212-3A patent/BR112018003212A2/en not_active Application Discontinuation
- 2016-08-17 US US15/238,950 patent/US10195170B2/en active Active
- 2016-08-17 CN CN201680048207.3A patent/CN108349867B/zh active Active
- 2016-08-17 EP EP16837725.7A patent/EP3337782A4/en not_active Withdrawn
- 2016-08-17 EP EP22204951.2A patent/EP4147694A1/en not_active Withdrawn
- 2016-08-17 KR KR1020187006526A patent/KR20180037261A/ko not_active Ceased
- 2016-08-17 CA CA2994987A patent/CA2994987C/en active Active
- 2016-08-17 RU RU2018109237A patent/RU2729066C2/ru active
- 2016-08-17 TW TW105126278A patent/TWI743047B/zh active
- 2016-08-17 MX MX2018002049A patent/MX2018002049A/es unknown
- 2016-08-17 AU AU2016308121A patent/AU2016308121A1/en not_active Abandoned
- 2016-08-17 WO PCT/US2016/047272 patent/WO2017031161A1/en not_active Ceased
- 2016-08-17 JP JP2018508748A patent/JP6887987B2/ja active Active
-
2018
- 2018-02-06 IL IL257379A patent/IL257379A/en unknown
-
2021
- 2021-01-11 AU AU2021200117A patent/AU2021200117B2/en not_active Ceased
- 2021-05-18 JP JP2021083646A patent/JP2021121605A/ja active Pending
-
2023
- 2023-03-22 JP JP2023045240A patent/JP2023078360A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4147694A1 (en) | 2023-03-15 |
| JP2018523687A (ja) | 2018-08-23 |
| JP2021121605A (ja) | 2021-08-26 |
| CN108349867A (zh) | 2018-07-31 |
| RU2729066C2 (ru) | 2020-08-04 |
| CN108349867B (zh) | 2021-03-09 |
| JP2023078360A (ja) | 2023-06-06 |
| AU2016308121A1 (en) | 2018-03-01 |
| RU2018109237A (ru) | 2019-09-19 |
| EP3337782A1 (en) | 2018-06-27 |
| CA2994987A1 (en) | 2017-02-23 |
| US10195170B2 (en) | 2019-02-05 |
| EP3337782A4 (en) | 2019-04-03 |
| RU2018109237A3 (https=) | 2019-12-31 |
| TWI743047B (zh) | 2021-10-21 |
| AU2021200117A1 (en) | 2021-03-18 |
| TW201717927A (zh) | 2017-06-01 |
| MX2018002049A (es) | 2018-06-15 |
| AU2021200117B2 (en) | 2023-09-28 |
| HK1254388A1 (zh) | 2019-07-19 |
| WO2017031161A1 (en) | 2017-02-23 |
| BR112018003212A2 (en) | 2018-09-25 |
| CA2994987C (en) | 2023-09-26 |
| JP6887987B2 (ja) | 2021-06-16 |
| KR20180037261A (ko) | 2018-04-11 |
| US20170049733A1 (en) | 2017-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL257379A (en) | Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex | |
| IL269642A (en) | Methods and compositions for enhancing health | |
| IL249061A0 (en) | Combination, composition, and method of administering the combination or composition to animals | |
| IL257978B (en) | Use of pasteurized akkermansia for treating metabolic disorders | |
| IL257279A (en) | Stable anti-ifnar1 formulation | |
| EP3302275A4 (en) | WELDING DISPLAY OF PHYSIOLOGICAL CONDITIONS | |
| LT3302565T (lt) | Kietos palbociklibo dozavimo formos | |
| LT3253865T (lt) | Metodai, skirti sustiprinti terapinių imuninių ląstelių veiksmingumą | |
| PL3186244T3 (pl) | Analogi dioksolanowe urydyny w leczeniu raka | |
| EP3329400A4 (en) | DISAMBING OF SEARCH QUESTIONS | |
| EP3406336A4 (en) | NANO FOIL OF CORE CASE STRUCTURE TYPE | |
| IL256206A (en) | Mct4 inhibitors for treating disease | |
| IL242971B (en) | Ventricular far field reduction | |
| PT3313418T (pt) | Composições de crioprecipitado e métodos de preparação das mesmas | |
| EP3399957A4 (en) | COMPOSITION FOR VIEWING | |
| KR101976358B9 (ko) | 로봇의 안전성 향상 방법 | |
| CL2015003493S1 (es) | Mueble. | |
| UY35747A (es) | Derivados sustituidos de fenilalanina | |
| EP3610851A4 (en) | COMPOSITION OF SKIN CLEANSING AGENT | |
| PL3487491T3 (pl) | Kompozycje do zwiększenia aktywności mózgu | |
| BR112017021527A2 (pt) | dentifrícios com base em cálcio para acentuar absorção de ingredientes ativos. | |
| EP3316879A4 (en) | TOPICAL DIACEREIN OR RHEIN FORMULATIONS AND USES THEREOF | |
| DK3352804T3 (da) | Artikel, der klæber til huden | |
| EP3359962A4 (en) | BLOOD PREPARATION AND PROFILING | |
| EP3383401A4 (en) | THIENOPYRIMIDINE DERIVATIVES AND USES THEREOF |